menu search

ABCL / AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs. Read More
Posted: Jun 6 2022, 07:24
Author Name: Seeking Alpha
Views: 110617

ABCL News  

AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

AbCellera Biologics Inc. (ABCL) Q3 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & more_horizontal

New Strong Buy Stocks for October 26th

By Zacks Investment Research
October 26, 2023

New Strong Buy Stocks for October 26th

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023. more_horizontal

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

By Business Wire
October 11, 2023

AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023. more_horizontal

3 AI Stocks You'll Regret Not Buying Soon

By InvestorPlace
August 8, 2023

3 AI Stocks You'll Regret Not Buying Soon

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatmen more_horizontal

AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 3, 2023

AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & C more_horizontal

Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?

By Zacks Investment Research
July 25, 2023

Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiv more_horizontal

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

By InvestorPlace
July 8, 2023

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been a more_horizontal

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

By Business Wire
May 29, 2023

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, more_horizontal


Search within

Pages Search Results: